Beta-lactam antibiotic administration in critically ill children with sepsis: an international survey of current practice

Authors:
  • TGthe Australian and New Zealand Intensive Care Society Paediatric Study Group
    the Australian and New Zealand Intensive Care Society Paediatric Study Group
  • TKTatjana Kerig
    Tatjana Kerig

Abstract
Objective: To assess current international practices and perceptions regarding beta-lactam antibiotic administration in critically ill children with sepsis. Design, setting, and participants: An electronic survey was distributed among physicians, advanced nurse practitioners and pharmacists working in paediatric intensive care units (PICUs) through PICU research networks from April to August 2024. Main outcome measures: Demographic characteristics, current practices of beta-lactam (meropenem, piperacillin/tazobactam and cefotaxime) administration, reasons for infusion method choices, and perceptions on the efficacy of continuous and extended infusions. Results: Two hundred sixty clinicians responded (236 physicians, 21 pharmacists, 2 advanced nurse practitioners) from 18 countries and 5 continents. Most respondents (88.1%) indicated use of beta-lactams as first-line antibiotics for children with sepsis, with intermittent infusion as the predominant standard practice across the selected beta-lactams (meropenem, 50.2%; piperacillin/tazobactam, 68.5%; and cefotaxime, 82.8%). Among respondents who opted for a continuous or extended infusion on an individual patient basis, 55.0% cited higher severity of illness as the primary reason for choosing this method for meropenem. The majority of respondents (86.5%) agreed there is lack of evidence to embed continuous and/or extended beta-lactam infusions into clinical practice and would recruit (84.6%) to a randomised controlled trial comparing continuous and/or extended and intermittent infusion. Conclusions: This international survey highlights the lack of evidence in beta-lactam administration practices in treating critically ill children with sepsis. There is a clear need and desire for further research through randomised controlled trials to establish optimal beta-lactam infusion methods and investigate their impact on clinical outcomes in the paediatric patient population.

This publication has 18 references indexed in Scilit: